Search

Probiotic Efficacy Evaluation Service in Cancer Models

Creative Biolabs provides probiotic efficacy evaluation services in cancer models to determine how candidate strains affect tumor control, survival, immune infiltration, treatment response, microbiome composition, metabolites, and safety. Our oncology-focused team designs interpretable monotherapy and combination studies that reduce model-related confounding and deliver decision-ready evidence for candidate selection, mechanism planning, and preclinical development.

Unlocking the Therapeutic Potential of Probiotics in Cancer

Microbiome-focused biotech and immuno-oncology teams must separate a candidate strain's contribution from variation introduced by tumor model biology, background microbiota, treatment timing, dosing, and combination partners. A simple tumor-volume comparison rarely explains whether an observed response is direct, immune-mediated, metabolite-driven, or dependent on restoration of a disrupted microbial community. Without disciplined controls, this complexity can obscure a promising signal or create an apparent effect that is difficult to reproduce.

Probiotics may influence cancer progression and treatment response through immune, metabolic, barrier, and tumor-microenvironment pathways, but each hypothesis requires a fit-for-purpose model and aligned endpoints. Creative Biolabs provides customized in vivo cancer-model studies that connect efficacy, safety, immune profiling, microbiome analysis, and mechanism-oriented readouts in one coherent program. The output supports clear program decisions.

One study logic, multiple evidence layers

Match the cancer model, comparator arms, administration plan, sampling schedule, and analytical endpoints to the decision your team needs to make.

Comprehensive Probiotic Efficacy Evaluation in Cancer Animal Models

At Creative Biolabs, we provide end-to-end preclinical research support for the complex relationship among probiotics, host microbiota, tumor biology, and treatment response. Our service is designed to generate robust, interpretable evidence for candidate prioritization, combination strategy development, investment diligence, and preclinical data-package planning.

Syngeneic Mouse Models

CT26 and MC38 colon cancer, B16F10 melanoma, 4T1 breast cancer, Lewis lung carcinoma, and other immunocompetent systems for investigating immune-mediated antitumor effects and combination treatment response.

Xenograft Models

Human cancer cell lines such as HCT116, HT29, A549, and PC-3 implanted in suitable immunodeficient hosts for evaluating direct antiproliferative, metabolic, formulation, or exposure-related hypotheses.

Physiologically Relevant Models

Genetically engineered, orthotopic, and chemically induced systems, including AOM/DSS-associated colorectal cancer, can support questions involving cancer initiation, tissue context, inflammation, and disease progression.

Metastasis Models

Tail-vein, splenic, and orthotopic designs can be considered when the key objective is metastatic seeding, organ-specific burden, dissemination, or survival rather than only primary tumor growth.

Model-selection logic: We evaluate tumor immunogenicity, host immune status, microbial baseline, treatment sensitivity, implantation site, expected study duration, and the intended mechanism before recommending a system.

Route and Form

Oral gavage, dietary supplementation, enema, or another scientifically justified route, with live culture, lyophilized powder, encapsulated material, or defined formulation handled according to agreed conditions.

Dose and Schedule

Single-dose screening or dose-ranging designs can identify an active range and clarify exposure-response behavior. Frequency and duration are aligned with strain viability, tumor kinetics, and the mechanism hypothesis.

Monotherapy and Combination Arms

Comparator groups can distinguish probiotic-only effects from additive, synergistic, antagonistic, or toxicity-modifying responses with chemotherapy, radiotherapy, immunotherapy, or targeted treatment.

Confounding control: Randomization, vehicle and combination controls, cage strategy, acclimation, antibiotic history, feed, sampling order, viable-count verification, and prespecified analysis are considered during protocol design.

Tumor Growth and Survival

Serial caliper measurement for subcutaneous tumors; bioluminescence imaging for suitable luciferase-expressing orthotopic or metastatic models; tumor burden, time-to-event, survival, gross pathology, and histopathological evaluation.

Immune System Analysis

Flow cytometry for T cells, B cells, NK cells, macrophages, dendritic cells, MDSCs, and Tregs in tumors and systemic compartments; cytokine and chemokine measurement by ELISA or multiplex assays; IHC or IF for spatial infiltration; and ELISpot for selected antigen-specific responses.

Microbiome Analysis

16S rRNA Gene Sequencing profiles community structure and diversity, while Shotgun Metagenomic Sequencing supports higher-resolution taxonomic and functional interpretation. Feces, gut content, mucosal samples, and selected tumor specimens can be incorporated according to the study question.

Metabolomics and Proteomics

Short-Chain Fatty Acid (SCFA) Analysis can quantify acetate, propionate, and butyrate by suitable chromatography-based methods. Broader targeted or untargeted metabolite and protein profiling can identify host-microbial pathways associated with treatment response.

Molecular and Tissue Endpoints

RT-qPCR or RNA-seq for cancer, immune, barrier, and metabolic pathways; H&E and specialized staining; pathology scoring for inflammation, necrosis, and fibrosis; and selected protein-expression measurements to connect phenotype with mechanism.

Toxicity and Tolerability

Body weight, food intake when relevant, clinical observations, organ weight, gross pathology, hematology, blood chemistry, and tissue findings provide context for efficacy and help distinguish treatment benefit from nonspecific intolerance.

Sample Information and Submission for Client-Provided Candidates

Strain identity: Genus, species, strain designation, source, relevant genotype or phenotype, and any engineered features.

Formulation: Live culture, frozen stock, lyophilized powder, encapsulated material, excipients, and reconstitution instructions.

Viability: Current CFU per unit or dose, enumeration method, expected variability, and acceptance range when available.

Storage and handling: Temperature, light, humidity, thawing, mixing, oxygen exposure, and hold-time limitations.

Safety information: Existing in vitro or in vivo findings, antimicrobial-resistance information, contaminant controls, and relevant qualification history.

Program context: Target cancer, hypothesized mechanism, prior efficacy data, planned combination partner, and the development decision the study should support.

12-25

Typical project weeks

Turnaround depends on model establishment, tumor kinetics, acclimation or microbiota-conditioning requirements, intervention duration, sample number, and the analytical package selected.

Your customized proposal will define study milestones, sampling windows, data-transfer points, analysis dependencies, and the expected draft and final report schedule.

Probiotic Cancer Model Study Workflow

The five-stage workflow follows the supplied process logic while adding oncology-specific controls, sampling decisions, and interpretation checkpoints.

01

Consultation and Study Design

Objectives, candidate strain, cancer model, treatment arms, confounders, endpoints, and success criteria.

02

Animal Acclimation and Modeling

Acclimation, baseline collection, microbiota-conditioning when required, model induction, randomization, and dosing readiness.

03

In-Life and Laboratory Analysis

Probiotic administration, tumor monitoring, tolerability, scheduled biospecimens, necropsy, and endpoint assays.

04

Data Analysis and Interpretation

Prespecified statistics, integrated efficacy and safety review, immune and microbial associations, and MoA interpretation.

05

Reporting and Data Transfer

Quality-reviewed report, methods, figures, statistical outputs, raw data, interpretation, and next-step recommendations.

Probiotic Cancer Model Study Deliverables and Data Package

Each package is structured so scientific teams can trace conclusions back to methods, statistical outputs, and source data.

Deliverable Component Content Specifications Decision Value
Comprehensive Study Report Executive summary, detailed materials and methods, protocol deviations when applicable, results, graphs, tables, statistical analysis, interpretation, conclusions, and raw-data appendices. Supports internal review, partner diligence, candidate prioritization, and planning of confirmatory or mechanism studies.
Raw and Processed Data Files Assay-specific source files such as flow-cytometry FCS files, sequencing FASTQ files, plate-reader outputs, image data, clinical observations, and analysis-ready datasets. Enables auditability, sponsor-side reanalysis, biomarker exploration, and integration with broader program datasets.
Publication-Quality Visuals High-resolution figures, tumor-growth curves, survival plots, immune profiles, microbiome summaries, pathology images, and statistical annotations selected for the final report. Makes cross-functional review faster and helps teams communicate the strength and limits of the evidence clearly.
Scientific Interpretation Integrated assessment of efficacy, combination effects, tolerability, immune changes, microbial shifts, metabolites, and concordance among endpoints. Clarifies whether the candidate should advance, be reformulated, be retested at another dose, or move into focused MoA work.

Advance Your Probiotic Cancer Research with a Decision-Ready Study

Contact our scientific team for a confidential discussion of your strain, cancer model, combination strategy, endpoints, and development objective.

Applications of Probiotic Efficacy Studies in Cancer Models

A tailored study can answer distinct development questions from lead selection through combination strategy and preclinical package planning.

Efficacy Screening

Identify strains with reproducible effects on tumor burden, survival, or treatment response.

Combination Evaluation

Assess effects alongside chemotherapy, radiotherapy, immunotherapy, or targeted agents.

Biomarker Discovery

Explore host, immune, microbial, and metabolite features associated with response.

Safety and Formulation

Compare dose, delivery format, viability, tolerability, and administration conditions.

Preclinical Packages

Generate structured efficacy and mechanism evidence for downstream planning.

Probiotic Mechanism-of-Action Endpoints in Cancer Models

Mechanism-oriented endpoints connect tumor response with immune, metabolic, barrier, tissue, and treatment-modifying effects.

Immune Modulation

Profile T cells, NK cells, macrophages, dendritic cells, cytokines, Tregs, MDSCs, and spatial immune infiltration.

Metabolic Modulation

Measure SCFAs, bile-acid-related signals, nutrients, and broader microbial or host metabolites associated with response.

Direct Tumor-Associated Effects

Interrogate cell-cycle control, apoptosis, angiogenesis, gene expression, and tissue pathology.

Gut Barrier and Inflammation

Assess barrier-associated tissues and inflammatory mediators linked to microbial translocation and systemic effects.

Treatment Efficacy and Toxicity Modulation

Use aligned combination arms to distinguish enhanced antitumor activity from mitigation of gastrointestinal or systemic treatment burden.

Published Data Supporting Probiotic Evaluation in Cancer Models

Probio-M9 and anti-PD-1 combination study in CT26 tumor-bearing mice. (OA Literature)
Fig.1 Effect of host microbiota modulation on antitumor therapy by anti-programmed cell death protein-1 (PD-1) antibody. 1,2

Recent research used a CT26 colorectal cancer model to test a probiotic alone and together with anti-PD-1 treatment after antibiotic-mediated microbiota disruption. The experimental design linked longitudinal tumor measurements and survival with staged fecal collection and shotgun metagenomic analysis. The published data indicate that the combination arm produced stronger tumor suppression than anti-PD-1 treatment without probiotic supplementation, while the probiotic-only arm did not show the same tumor-control effect.

This study matters for probiotic cancer-model services because it demonstrates why monotherapy, combination, microbiota-background, and time-matched sampling arms must be designed together. It also shows that tumor response should be interpreted alongside microbial recovery and functional metagenomic changes, not as an isolated endpoint. Creative Biolabs can translate this evidence logic into customized model selection, comparator design, tumor and survival monitoring, immune analysis, microbiome sequencing, and integrated reporting for client candidates.

Advantages of Partnering with Creative Biolabs

Integrated expertise and flexible execution for decision-ready cancer-model studies.

01

Expertise

Oncology, immunology, microbiology, and pharmacology.

02

Platforms

Integrated animal, sequencing, imaging, and omics capabilities.

03

Customization

Models and endpoints aligned to your decision.

04

Mechanistic Depth

Connected tumor, immune, microbial, and metabolic evidence.

05

Quality

Defined controls, data review, and traceable outputs.

06

Data Readiness

Practical reports for downstream development planning.

07

Confidentiality

Protected communication, strain information, and sponsor data.

In Vivo

Tumor models

Immune

Cell and cytokine profiling

Microbiome

16S and metagenomics

Multi-Omics

Metabolites and expression

Pathology

Tissue endpoints

Frequently Asked Questions

Yes. We can accommodate diverse strains and formulations after a feasibility review. Taxonomic identity, formulation, viable count, storage and handling requirements, safety information, and any engineered features help us define receipt, preparation, dosing, containment, and quality-control procedures.

Yes. Bioinformatics and statistical analysis can connect taxonomic composition, diversity, functional potential, longitudinal changes, treatment arms, and relevant efficacy or immune endpoints. Interpretation is framed around the prespecified biological question and the limits of the sampling design.

Cost depends on the model, animal number, treatment arms, study duration, sample schedule, imaging needs, immune panels, sequencing depth, multi-omics scope, pathology, and reporting requirements. We provide an itemized customized proposal after a scientific consultation.

We align comparator arms, randomization, cage and feed strategy, acclimation, treatment timing, viable-dose verification, baseline sampling, tumor monitoring, and prespecified statistics. The final design depends on the candidate and model, but the goal is to separate probiotic, combination-partner, background-microbiota, and tolerability effects.

A typical total duration is approximately 12 to 25 weeks. Model establishment, intervention schedule, survival follow-up, sample number, sequencing, pathology, and integrated analysis can change the timeline. A project-specific schedule is included in the proposal.

Other Resources

Creative Biolabs Live Biotherapeutics service brochure

Creative Biolabs' Live Biotherapeutics - Brochure

Probiotic strain products for NGP research brochure

Probiotic Strain Products for NGP Research - Brochure

Custom small-scale probiotic production brochure

Custom Small-scale Probiotic Production - Brochure

Live biotherapeutics research services video

Live Biotherapeutics - Creative Biolabs - Video

References

  1. Gao, Guangqi, et al. "Adjunctive probiotic Lactobacillus rhamnosus Probio-M9 administration enhances the effect of anti-PD-1 antitumor therapy via restoring antibiotic-disrupted gut microbiota." Frontiers in Immunology 12 (2021): 772532. https://doi.org/10.3389/fimmu.2021.772532
  2. Distributed under Open Access license CC BY 4.0, without modification.
Online Inquiry

For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.

Creative Biolabs-Live Biotherapeutics


ISO 9001 Certified - Creative Biolabs Quality Management System.
Contact us
Solutions

Copyright © 2026 Creative Biolabs. All Rights Reserved.

Inquiry Basket